Pennant Group
PNTG
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$21.1m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$36.95
+21.2% in the quarter
Share price change by quarter
+53.9%Q3 ’24
-25.7%Q4 ’24
-5.2%Q1 ’25
+18.7%Q2 ’25
-15.5%Q3 ’25
+11.6%Q4 ’25
+8.3%Q1 ’26
+21.2%Q2 ’26
Managers holding it, by quarter
1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
2Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Who holds it
| First Eagle Investment Management | 0.0%$21.1m | Added +32% |
Directors buying and selling
How this works
| Bought or sold | ||||
|---|---|---|---|---|
| 6 Aug 2026 | Guerisoli BrentChief Executive Officer | ▼ Sold | 4,285 | $165k |
| 6 Aug 2026 | Steik Jason PaulChief Clinical Officer | ▼ Sold | 1,394 | $54k |
| 6 Aug 2026 | Cheney Kirk SterlingEVP, GC and Corp Secy | ▼ Sold | 1,393 | $54k |
About the company
- Sector
- Health care · Services-Health Services
- Incorporated in
- Delaware
- Financial year ends
- 31 December
- Shares outstanding
- 35m at 3 Aug 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$251m2017
$286m2018
$339m2019
$391m2020
$440m2021
$473m2022
$545m2023
$695m2024
$948m2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $948m | $29.6m |
| 2024 | $695m | $22.6m |
| 2023 | $545m | $13.4m |
| 2022 | $473m | $6.6m |
| 2021 | $440m | $2.7m |
| 2020 | $391m | $15.7m |
| 2019 | $339m | $2.5m |
| 2018 | $286m | $15.7m |
| 2017 | $251m | $9.9m |